Substance / Medication

Colistimethate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Pseudomonas infection

Urinary tract infectious disease

Colibacillosis

Bacterial infectious disease

Infection caused by Klebsiella

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline

NCT06893835Phase 4Active Not Recruiting132 enrolled

Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection

NCT06570850Phase 4Recruiting188 enrolled

Pharmacokinetics of Colistin in Critically-ill Patients With AKI Who Receive SLED

NCT05586438Phase 4Completed13 enrolled

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

NCT03397914Phase 4Completed70 enrolled

A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)

NCT02966457Phase 4Completed62 enrolled

View all 7 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.

Tappenden P, Harnan S, Uttley L et al. · Health Technol Assess · 2013

PMID: 24290164Meta-AnalysisFull text (PMC)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.

Uttley Lesley, Harnan Sue, Cantrell Anna et al. · Eur Respir Rev · 2013

PMID: 24293463Meta-AnalysisFull text (PMC)

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.

Haworth Charles S, Shteinberg Michal, Winthrop Kevin et al. · Lancet Respir Med · 2024

PMID: 39270696RCT

Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria.

Rattanaumpawan Pinyo, Lorsutthitham Jintana, Ungprasert Puangpaka et al. · J Antimicrob Chemother · 2010

PMID: 20876621RCT

In vitro neurotoxicity comparison: Colistimethate induces higher toxicity than colistin via formaldehyde accumulation.

Lu Jing, Zhu Yan, Li Mengyao et al. · Int J Antimicrob Agents · 2025

PMID: 40975188Observational

Acute kidney injury of intravenous colistin sulfate compared with colistimethate sodium: a real-world, retrospective cohort study.

Yang Ping, Shuai Wuping, Ju Yuanzhi et al. · BMC Infect Dis · 2025

PMID: 40781278ObservationalFull text (PMC)

Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry.

Kaplan Sigal, Lee Andrew, Caine Noreen et al. · J Cyst Fibros · 2021

PMID: 32807645Observational

Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes.

Thammathiwat Theerachai, Tiranathanagul Khajohn, Srisawat Nattachai et al. · Nephrology (Carlton) · 2020

PMID: 31509307Observational

Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.

Moni Merlin, Sudhir A Sangita, Dipu T S et al. · Int J Infect Dis · 2020

PMID: 32781161Observational

Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.

Somayaji Ranjani, Russell Renee, Cogen Jonathan D et al. · Ann Am Thorac Soc · 2019

PMID: 30840835ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Colistimethate (substance)
SNOMED CT: 82885001
UMLS CUI: C0009315

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.